PVT1 and gastric adenocarcinoma: In the present study, we first established a prognostic signature consisting of four ARLncs (PVT1, LINC01315, AC245041.1, and AC037198.1) for STAD patients, which was verified as a key prognostic predictor and may serve as a potential therapeutic target for STAD.